Analysis of MIST's PDUFA Catalyst & RVPH Complementary Pick Claims

A Reddit user posted due diligence on

highlighting key catalysts:

• FDA PDUFA date for CARDAMYST™ (etripamil nasal spray for PSVT) on
  December 13, 2025
  (confirmed by Milestone’s Q3 2025 report [1])
• $82 million cash runway (unconfirmed, requires further verification)
• $75 million royalty payment upon FDA approval (mentioned in Milestone’s Q2 2025 forward-looking statements [1])
• The user holds 4,000 shares at $1.82 and expects the stock to rise as the catalyst approaches.

The post also described

as a “great complementary pick” to MIST.

• Price Movement
  : From November 17 to November 28, MIST’s stock price increased by
  15.95%
  (closing at $2.32 on Nov17 vs. $2.69 on Nov28) [0].
• Volume
  : High trading volume was observed on November17 (9.45M shares) and November18 (6.25M shares), indicating increased investor interest [0].
• News Catalysts
  : Jefferies lifted MIST’s price target to $2 from $1 on November25 [2], contributing to gains on November25 (+2.49%) and November26 (+6.97%) [0].

• Historical Performance
  : RVPH has underperformed significantly over two years, with a
  total return of -85.86%
  and annualized return of -62.39% [3]. This raises concerns about its suitability as a complementary pick to MIST.

Metric	MIST	RVPH
Recent Price (Nov28)	$2.69	$0.56
10-Day Price Change (Nov17-Nov28)	+15.95%	N/A
2-Year Total Return	N/A	-85.86%
Key Catalyst	FDA PDUFA (Dec13,2025)	None identified
Analyst Price Target (Jefferies)	$2.00	N/A

• RVPH-MIST Link
  : No evidence was found to support the claim that RVPH is a complementary pick to MIST (e.g., shared sector, supply chain, or clinical pipeline alignment).
• MIST Cash Runway
  : The $82 million cash runway mentioned in the Reddit post requires verification from official financial reports.
• RVPH Fundamentals
  : No recent financial data or catalysts were identified for RVPH to justify its “great pick” label.

• MIST
  : While the PDUFA catalyst is positive, Jefferies’ price target of $2 is below the current price ($2.69), suggesting limited upside unless approval is accompanied by stronger-than-expected commercial prospects [2].
• RVPH
  : The stock’s poor historical performance (2-year loss of 85.86%) indicates significant risk, and investors should question the complementary pick claim [3].

• FDA Approval Uncertainty
  : A negative PDUFA outcome could lead to a sharp decline in MIST’s stock price.
• Valuation
  : Current price ($2.69) exceeds Jefferies’ revised target ($2.00), which may limit short-term gains [2].

• Historical Underperformance
  : Users should be aware that RVPH’s 2-year total return of -85.86% may significantly impact investment decisions [3].
• Lack of Catalysts
  : No positive catalysts were identified for RVPH to reverse its downward trend.

• MIST
  : FDA decision on December13, 2025; commercialization plans post-approval; verification of cash runway.
• RVPH
  : Any new catalysts (e.g., clinical trial updates, partnerships) that could justify its complementary pick status.